Open AccessSuccessful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
Author(s) -
Nakako Soichiro,
Takakuwa Teruhito,
Ichimura Hirona,
Okamura Hiroshi,
Nanno Satoru,
Nishimoto Mitsutaka,
Nakashima Yasuhiro,
Koh Hideo,
Hino Masayuki,
Nakamae Hirohisa
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4298
Subject(s) - aclarubicin , medicine , cytarabine , azacitidine , tegafur , chronic myelomonocytic leukemia , decitabine , oncology , gastroenterology , leukemia , chemotherapy , myelodysplastic syndromes , bone marrow , dna methylation , biochemistry , gene expression , chemistry , gene
A 55‐year‐old man was diagnosed with therapy‐related chronic myelomonocytic leukemia (t‐CMML) after exposure to tegafur/gimeracil/oteracil. Although he was refractory to hydroxyurea and low‐dose cytarabine, combination therapy with cytarabine, aclarubicin and azacitidine (CA‐AZA) provided good disease control, and he underwent allogeneic stem cell transplantation. This report has two key massages. First, tegafur/gimeracil/oteracil may have a potential risk of developing t‐CMML. Second, CA‐AZA therapy may be considered as a therapeutic option for patients with t‐CMML.